Antidiabetic Properties of Rose Hip
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01316016 |
Recruitment Status
:
Completed
First Posted
: March 16, 2011
Last Update Posted
: March 16, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity | Dietary Supplement: Rose hip | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 31 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Effects of Rose Hip Intake on Risk Markers of Type 2 Diabetes and Cardiovascular Disease: a Randomized Double-blind Cross-over Investigation in Obese Persons |
Study Start Date : | April 2009 |
Actual Primary Completion Date : | February 2010 |
Actual Study Completion Date : | January 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: Rose hip |
Dietary Supplement: Rose hip
40 g of rose hip powder daily for 6 weeks.
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- BMI > 30
- willingness to participate in the study
- willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study
Exclusion Criteria:
- diabetes
- previous or ongoing insulin treatment
- abnormal thyroid status
- abnormal liver status
- abnormal kidney status
- known gastrointestinal disorder
- pregnancy
- suspected allergy to ingredients of the drinks

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01316016
Sweden | |
Endocrinology Clinic, Lund University Hospital | |
Lund, Sweden, SE-22185 |
Study Chair: | Per Katzman, MD/PhD | Lund University |
Publications:
Responsible Party: | Cecilia Holm, Lund University |
ClinicalTrials.gov Identifier: | NCT01316016 History of Changes |
Other Study ID Numbers: |
LUAFC002 |
First Posted: | March 16, 2011 Key Record Dates |
Last Update Posted: | March 16, 2011 |
Last Verified: | February 2011 |
Keywords provided by Lund University:
obesity glucose intolerance cholesterol blood pressure |